Market Overview

Merck, GE Healthcare Announce Collaboration on Use of Imaging Biomarkers for Investigational BACE Inhibitor Program

Share:
Related MRK
Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates
Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow
Related GE
Jim Cramer Weighs In On General Electric And Take Two Interactive Software
Benzinga's Top Upgrades, Downgrades For April 25, 2017
Weekly Top Insider Buys Highlight for the Week of April —8 (GuruFocus)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration, license and supply agreement for use of [^18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

Accumulation of beta amyloid in the brain is a pathological characteristic related to Alzheimer's disease. Currently, AD is diagnosed by clinical examination (i.e., medical history, physical, neurological, psychiatric and neuropsychological exams, laboratory tests and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be confirmed through histopathological identification of characteristic features, including beta amyloid plaques, in post-mortem brain samples.

Posted-In: News

 

Related Articles (GE + MRK)

View Comments and Join the Discussion!